Format

Send to

Choose Destination
Vaccine. 2019 Mar 20. pii: S0264-410X(19)30167-7. doi: 10.1016/j.vaccine.2019.01.081. [Epub ahead of print]

Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Author information

1
Accelerated Disease Control and Surveillance Branch, Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: gbgrant@cdc.gov.
2
Immunisation and Vaccine Development Program, Regional Office for Africa, World Health Organization, Brazzaville, People's Republic of Congo.
3
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
4
Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
5
Viral Vaccine Preventable Diseases Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
6
Hubert Department of Global Health, Rollins School of Public Health, Emory University, United States.
7
Immunization Systems Branch, Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States.
8
Accelerated Disease Control and Surveillance Branch, Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States.
9
Bill and Melinda Gates Foundation, Seattle, Washington, United States.
10
School of Medicine and Public Health, University of Newcastle, Australia.

Abstract

The Measles & Rubella Initiative (M&RI) identified five key strategies to achieve measles and rubella elimination, including research and innovation to support cost-effective operations and improve vaccination and diagnostic tools. In 2016, the M&RI Research and Innovation Working Group (R&IWG) completed a research prioritization process to identify key research questions and update the global research agenda. The R&IWG reviewed meeting reports and strategic planning documents and solicited programmatic inputs from vaccination experts at the program operational level through a web survey, to identify previous research priorities and new research questions. The R&IWG then convened a meeting of experts to prioritize the identified research questions in four strategic areas: (1) epidemiology and economics, (2) surveillance and laboratory, (3) immunization strategies, and (4) demand creation and communications. The experts identified 19 priority research questions in the four strategic areas to address key areas of work necessary to further progress toward elimination. Future commitments from partners will be needed to develop a platform for improved coordination with adequate and predictable resources for research implementation and innovation to address these identified priorities.

KEYWORDS:

Eradication; Immunization; Measles; Research; Rubella; Vaccines

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center